Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MCHR2 | Q969V1 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19159359 | 0.84 | HTR2A (0.45) | CYP1A2L3MBTL1POLBRECQLHSD17B10 | |
| SCHEMBL6741338 | 0.79 | HRH3 (0.50) | HRH3SIGMAR1CYP1A2CYP2D6L3MBTL1 | |
| SCHEMBL6746000 | 0.77 | HRH3 (0.40) | HRH3SIGMAR1CYP2D6HSD17B10 | |
| SCHEMBL6744654 | 0.76 | QPCT (0.38) | MCHR1SIGMAR1MCHR2 | |
| SCHEMBL17678169 | 0.75 | KMO (0.58) | MCHR1SIGMAR1MCHR2 | |
| SCHEMBL6741094 | 0.74 | BRD4 (0.38) | MCHR1SIGMAR1MCHR2L3MBTL1POLB | |
| SCHEMBL6740873 | 0.73 | KMO (0.39) | MCHR1POLB | |
| SCHEMBL6739781 | 0.73 | KMO (0.56) | MCHR1HSD17B10 | |
| SCHEMBL18731898 | 0.73 | KMO (0.56) | HRH3MCHR1SIGMAR1MCHR2L3MBTL1 | |
| SCHEMBL28264567 | 0.73 | SIGMAR1 (0.55) | HRH3SIGMAR1CYP1A2CYP2D6L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | HRH3 21/4885MCHR1 457/4885SIGMAR1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.